Table 2.
Characters of stem cell-based therapy in treating AS syndrome.
| Authors/year | Cell source | Transplant cell type | Cell number (106) | Transplanted section | HT | Follow up (months) |
|---|---|---|---|---|---|---|
| Singh et al. 2014 | Bone marrow | Mononuclear stem cells | 103.3 ± 20.45 | Subendometrial transmyometrium injection (fundus, anterior, posterior) |
Oral estradiol valerate, 6 mg/day (12 weeks). Medroxy progesterone (last 10 days). Patients (started menstruation): Shifted to cyclical oral estrogen valerate 2 mg (tid, day 1 to day 26), progesterone 10 mg daily (day 16 to day 25). |
9 |
|
| ||||||
| Santamaria et al. 2016 | Per blood mobilization | CD133+ bone marrow Derived stem cells |
123.6 | Infusion into spiral arterioles | Hormonal replacement therapy (Progyluton™) | 6 |
|
| ||||||
| Tan et al. 2016 | Menstrual blood | Menstrual blood Derived stromal cells |
106 (5 patients), 106 × 2 (2 patients) |
Instill into uterus fundus | MenSCs collection (day 5), oestradiol (4 mg, 14 day). MenSCs transplant, oestradiol (6 mg, 21 day). ET < 7 mm: progesterone injection 40 mg. |
6 |
|
| ||||||
| Zhao et al. 2016 | Bone marrow | BM-mononuclear stem cells loaded in collagen scaffold | 4 cm × 6 cm scaffold (5 × 106 cm2) |
Attach to the uterine wall | Progynova (6 mg, 10 days), operation, continuous Progynova (6 mg, 30 days), progesterone injection (60 mg, 30th day) | 3 |
|
| ||||||
| Cao et al. 2018 | Umbilical cord | Umbilical cord-derived Mesenchymal stromal cells |
10 | Attach to the uterine wall | Progynova (6 mg, 10 days), operation, continuous Progynova (6 mg, 30 days), progesterone injection (60 mg, 30th day) | 30 |
|
| ||||||
| Lee et al. 2019 | Adipose tissue | Adipose-derived MSCs loaded in stromal vascular fraction | 4.6 | Cervical instillation | Oral estradiol valerate (6 mg, day1 to day 25), Oral Medroxyprogesterone (10 mg, day 21 to day 25) |
23 |
|
| ||||||
| Singh et al. 2020 | Bone marrow | BM-mononuclear stem cells | 65.3 ± 37.2 | Subendometrial transmyometrium injection (fundus, anterior, posterior) |
Oral estradiol valerate (2 mg, Tid,12 weeks), ET > 6 mm: Medroxyprogesterone (10 mg, last 10 days in 12 week) ET < 6 mm: additional cycle. |
60 |
|
| ||||||
| Ma et al. 2020 | Menstrual blood | Menstrual blood stem Cells (MenSCs) |
10 | Endometrium | Oral estradiol (2 mg, Tid, 14 days) + additional 3 days(ET < 7 mm) |
NA |
AS: Asherman syndrome; G-CSF: granulocyte colony-stimulating factor; BM: bone marrow; Tid: three times daily; ET: endometrium thickness.